Bloomberg News

Cochlear Product Recall Costs May Exceeed A$35 Million, UBS Says

October 03, 2011

Oct. 4 (Bloomberg) -- Cochlear Ltd.’s cost of voluntarily recalling its Nucleus 5 range of hearing devices because of a manufacturing glitch may exceed A$35 million, UBS said.

It’s too early to predict the product’s return to market and six months remains the “minimum estimate,” UBS Sydney- based health-care analysts Andrew Goodsall and Dan Hurren said in a report today in which they reiterated a “sell” rating on the shares.

To contact the editor responsible for this story: Jason Gale at j.gale@bloomberg.net


Race, Class, and the Future of Ferguson
LIMITED-TIME OFFER SUBSCRIBE NOW

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

 
blog comments powered by Disqus